Figure 1.

PISCES protocol and blood collection. mRCC patients were randomly assigned to pazopanib 800 mg per day for 10 weeks, followed by a 2-week washout, then sunitinib 50 mg per day (4 weeks on, 2 weeks off, 4 weeks on) for 10 weeks, or the reverse sequence. Blood samples from patients were collected prospectively at baseline (T1), 10 weeks (T2) and 20 weeks (T3) after the start of anti-angiogenic therapy. R stands for randomization. OD stands for oral administration once daily. ^a 4 weeks on treatment → 2 weeks of matching placebo → 4 weeks on treatment.